Clinical trial
A Phase I Open-Label Study to Evaluate the Safety and Tolerability of Escalating Doses of GM-CT-01 in the Presence and Absence of 5-Fluorouracil (5-FU) in Subjects With Advanced Solid Tumors
NCT00054977 is registered in ClinicalTrials.gov with Galectin Therapeutics Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Open-Label Study to Evaluate the Safety and Tolerability of Escalating Doses of GM-CT-01 in the Presence and Absence of 5-Fluorouracil (5-FU) in Subjects With Advanced Solid Tumors
- Lead sponsor
- Galectin Therapeutics Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- February 28, 2003
- Completion date
- September 30, 2006
- Enrollment
- 40 (actual)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.
breast cancer, colorectal cancer, head and neck cancer, lung cancer, prostate cancer